DICE Therapeutics is a a biopharmaceutical company using its proprietary technology platform, DELSCAPE, to build a pipeline of oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. DELSCAPE is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs). Co.'s lead therapeutic candidate, S011806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in immunology indications. Co. is also developing oral therapeutic for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis. The DICE stock yearly return is shown above.
The yearly return on the DICE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the DICE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|